Prescribers and regulators may question the clinical need of compounded bioidentical hormone therapies (cBHT) and how they differ from FDA approved drug products. The argument for compounding identical hormones is no longer useful, given the number of estradiol products available in topical forms, but the differences between those and what compounders offer are still unique and significant.
Read More